IL284909A - Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome - Google Patents

Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome

Info

Publication number
IL284909A
IL284909A IL284909A IL28490921A IL284909A IL 284909 A IL284909 A IL 284909A IL 284909 A IL284909 A IL 284909A IL 28490921 A IL28490921 A IL 28490921A IL 284909 A IL284909 A IL 284909A
Authority
IL
Israel
Prior art keywords
derbet
syndrome
treating
nerve cells
specific drugs
Prior art date
Application number
IL284909A
Other languages
English (en)
Hebrew (he)
Original Assignee
Broad Inst Inc
Harvard College
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc, Harvard College, Univ New York filed Critical Broad Inst Inc
Publication of IL284909A publication Critical patent/IL284909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL284909A 2019-02-05 2021-07-18 Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome IL284909A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962801483P 2019-02-05 2019-02-05
US201962823281P 2019-03-25 2019-03-25
US201962916477P 2019-10-17 2019-10-17
PCT/US2020/015183 WO2020163102A1 (en) 2019-02-05 2020-01-27 Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome

Publications (1)

Publication Number Publication Date
IL284909A true IL284909A (en) 2021-09-30

Family

ID=71947919

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284909A IL284909A (en) 2019-02-05 2021-07-18 Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome

Country Status (9)

Country Link
US (1) US20220195457A1 (cg-RX-API-DMAC7.html)
EP (1) EP3921326A4 (cg-RX-API-DMAC7.html)
JP (2) JP7724157B2 (cg-RX-API-DMAC7.html)
KR (1) KR102985982B1 (cg-RX-API-DMAC7.html)
CN (1) CN113966400A (cg-RX-API-DMAC7.html)
CA (1) CA3128525A1 (cg-RX-API-DMAC7.html)
IL (1) IL284909A (cg-RX-API-DMAC7.html)
SG (1) SG11202107813RA (cg-RX-API-DMAC7.html)
WO (1) WO2020163102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
CN115707773A (zh) * 2021-08-20 2023-02-21 中国科学院深圳先进技术研究院 一种利用交感神经控制血管内皮细胞异质性的方法
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
WO2023108401A1 (zh) * 2021-12-14 2023-06-22 深圳先进技术研究院 重组载体及其构建方法和应用
AU2022425534A1 (en) 2021-12-30 2024-07-04 Regel Therapeutics, Inc. Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof
GB2621102A (en) * 2022-04-11 2024-02-07 Univ Ramot Treatment and Reversion of Dravet syndrome by CAV-2-Mediated Delivery of an SCN1A Expression Cassette
EP4507785A4 (en) * 2022-04-11 2026-06-03 Broad Inst Inc Activators for directed gene expression in neural cell populations, compositions and associated processes
US20240344041A1 (en) * 2022-11-22 2024-10-17 President And Fellows Of Harvard College Artificial protein to restore synaptic function
CN116024222B (zh) * 2022-11-30 2023-12-22 湖南家辉生物技术有限公司 一种导致婴儿严重肌阵挛性癫痫的nac1基因突变体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255424B (zh) * 2007-11-26 2013-02-27 广州医学院第二附属医院 与癫痫相关scn1a基因的启动子及其构建方法和临床应用
US10568307B2 (en) * 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
US10682424B2 (en) * 2015-03-31 2020-06-16 New York University Compositions and method for reducing seizures
CN116059236A (zh) * 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
CN117821509A (zh) * 2017-04-03 2024-04-05 编码治疗公司 组织选择性转基因表达

Also Published As

Publication number Publication date
WO2020163102A1 (en) 2020-08-13
JP7724157B2 (ja) 2025-08-15
EP3921326A4 (en) 2022-12-14
CN113966400A (zh) 2022-01-21
KR102985982B1 (ko) 2026-07-03
CA3128525A1 (en) 2020-08-13
JP2022519623A (ja) 2022-03-24
JP2025118768A (ja) 2025-08-13
SG11202107813RA (en) 2021-08-30
US20220195457A1 (en) 2022-06-23
EP3921326A1 (en) 2021-12-15
KR20210133227A (ko) 2021-11-05

Similar Documents

Publication Publication Date Title
EP3844830A4 (en) CATHODE AND ELECTROCHEMICAL DEVICE
EP3915166A4 (en) ELECTROLYTE AND ELECTROCHEMICAL DEVICE
CR20130245A (es) Medios y método para el tratamiento del linfoma difuso de células b grandes (dlbcl)
PL3595044T3 (pl) Akumulator i płyta elektrodowa
EP4254538A4 (en) ELECTRODE ASSEMBLY AND ELECTROCHEMICAL DEVICE
EP3863081A4 (en) POSITIVE ELECTRODE STRUCTURE AND SECONDARY BATTERY
EP3973588A4 (en) Electrolytic solution and electrochemical device using the same
IL281963A (en) Microelectrode array and uses thereof
EP3799165A4 (en) POSITIVE ELECTRODE ACTIVE MATERIAL, POSITIVE ELECTRODE PLATE, ELECTROCHEMICAL ENERGY STORAGE DEVICE AND DEVICE
HUE063011T2 (hu) Elektródalemezek, elektrokémiai eszköz és berendezés
PL3716364T3 (pl) Elektroda dodatnia i akumulator zawierający elektrodę dodatnią
BR112017014758A2 (pt) arranjo de eletrodos para monitoramento fisiológico e dispositivo que inclui ou utiliza o mesmo
EP2899791A4 (en) ELECTRODE ASSEMBLY AND ELECTROCHEMICAL DEVICE THEREFOR
EP3364861A4 (en) TRANSCUTANEOUS ANALYTIC SENSORS, APPLICATORS THEREFOR AND RELATED METHODS
EP3623467A4 (en) HIGHLY ACTIVE NK CELL AND ITS USE
EP3325698A4 (en) CELL CULTURE, TRANSPORT AND INVESTIGATION
IL290100A (en) Methods of identifying dopaminergic neurons and progenitor cells
EP3799170A4 (en) Positive electrode current collector, positive electrode piece, electrochemical device, and device
MA47283A (fr) Analyse épigénétique de thérapie cellulaire et méthodes associées
EP4059986A4 (en) Electrode and electrochemical device
EP4207354A4 (en) POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE
FI20155991A7 (fi) Elektrodimoduuli, sähkökemiallinenreaktori, ja vedenkäsittelylaite
IL286482A (en) Expanded nk cell fractions for transplantation in combination therapy
EP3676750C0 (en) BIOLOGICAL CELL DETECTION AND CELL LINEAGE TRACING
EP3550659A4 (en) ELECTRODE ASSEMBLY AND RECHARGEABLE BATTERY INCLUDING THE SAME